CHARLOTTETOWN, Prince Edward Island--(BUSINESS WIRE)--BIOVECTRA, a leading Canadian biotech and pharmaceutical CDMO has appointed Gordon C. McCauley, President and CEO of adMare BioInnovations and Steven Klosk CEO (retired) Cambrex Corporation, to its board of directors.
“Mr. Klosk and Mr. McCauley are innovative executives who offer a wealth of experience to the BIOVECTRA Board of Directors,” says Oliver Technow, CEO of BIOVECTRA. “BIOVECTRA’s ambitious growth plans will be well-supported through the considerable leadership and expertise that I know each will contribute as directors with our board.”
Gordon McCauley BA, MBA, ICD.D is an accomplished life science executive and investor, having served as president and senior executive of several health care enterprises. As President and CEO of adMare, Mr. McCauley leads its mission to build companies, ecosystems, and talent in the life sciences industry. adMare has over 25 portfolio companies that have attracted more than $1.4 billion of investment with a combined value of over $3 billion.
“I am excited to help as a director with BIOVECTRA,” says Gordon McCauley. “What an excellent example of the type of world-leading companies we can build in Canada. I know BIOVECTRA leadership care deeply about producing high quality products to better serve patient care. I look forward to helping BIOVECTRA scale new heights.”
Steven Klosk BS, JD is a consummate executive of the life sciences industry with over 25 years of experience of CDMO leadership. Mr. Klosk retired as CEO of Cambrex Corporation in 2020 after leading its sale to Permira, a global private equity firm. During his tenure Cambrex became a leading global and fully integrated supplier of drug substances, drug product and testing services across the entire drug life cycle to both the innovator and generic pharmaceutical markets. The company grew to over 2,000 employees spanning a network of 12 manufacturing and research and development sites in North America and Europe.
“I am thrilled to serve on the board of directors of this thriving CDMO which places care for patients, clients, and its team as integral to BIOVECTRA’s success,” explains Steven Klosk. “This is an exciting time in the life sciences industry, and I look forward to working with the board to help BIOVECTRA reach its optimal success.”
BIOVECTRA is a global biotech and pharmaceutical CDMO (contract development and manufacturing organization) that specializes in clinical-to-commercial scale production capabilities for: biologics, bioreagents, fermented small molecules, synthetic small molecules, and active pharmaceutical ingredients. Flexibility, creativity, process optimization and compliance are at the heart of our method. With over 550 employees and cGMP facilities in Prince Edward Island and Nova Scotia, Canada we assure our programs advance on time and with the highest quality outcomes.